Background: Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%-40% of cases occur in patients >70 years.
introduction
Non-small-cell lung cancer (NSCLC) represents 80% of cases of lung cancer and unfortunately remains the leading cause of cancer-related death in both men and women in the Western world [1] .
Older patients share a substantial part of the disease burden in NSCLC. Indeed, 50% of newly diagnosed cases of NSCLC are observed in patients >65 years of age, while 30%-40% of cases occur in patients >70 years [2] . Furthermore, data from the Surveillance, Epidemiology, and End Results registry indicate that the median age at diagnosis in NSCLC patients is 69 years [3] . In elderly patients, clinical trials have clearly demonstrated that single-agent chemotherapy offers a survival benefit, compared with best supportive care [4] . Regarding combination therapy, published results are conflicting and it is not clear whether combination therapy offers benefit compared with monotherapy or not [5, 6] . During the 2010 Meeting of the American Society of Clinical Oncology, Quoix et al. [7] presented the results of a randomized phase III trial in older NSCLC patients. This study randomly allocated 451 patients ( ‡70 years of age) to single-agent therapy (either gemcitabine 1150 mg/m 2 or vinorelbine 30 mg/m 2 ; both drugs on days 1 and 8) or to a platinum-based doublet (paclitaxel 90 mg/m 2 days 1, 8, and 15 and carboplatin area under the curve 6). This trial demonstrated a survival benefit in favor of doublet arm [median overall survival (OS): 6.2 versus 10.3 months; P < 0.00004]. Toxicity and treatment-related deaths were significantly higher in the doublet arm [7] . However, this trial should be fully published before its results can be recommended as standard of care.
On the basis of these trials, several expert panels recommend single-agent treatment with gemcitabine, vinorelbine, or docetaxel as the treatment of choice for older NSCLC patients [8, 9] .
Despite the high incidence of NSCLC in the elderly population, a significant underrepresentation of these patients in clinical trials has been recorded [10] ; furthermore, despite the data supported by the aforementioned older-specific clinical trials [4] [5] [6] , the likelihood of receiving any kind of treatment for NSCLC, and particularly chemotherapy, decreases significantly with age [11] [12] [13] [14] .
The objective of this analysis was to accurately determine the following: (i) the number of patients >70 years who were enrolled in all phase III trials in advanced/metastatic NSCLC conducted by the Lung Cancer Group of the Hellenic Oncology Research Group (HORG), (ii) the treatment-related toxicity observed in the older patients compared with their younger counterparts, and (iii) the differences in the trials' efficacy end points between younger and older patients.
patients and methods
We reviewed all completed phase III trials in advanced/metastatic NSCLC conducted by HORG, during the period 1996-2004. Only trials that were closed to accrual, with all patients having completed therapy, and that were analyzed for their primary objectives were eligible for this review. Protocols related to the studies as well as relevant publications were acquired to ensure accuracy of the data extraction. Data related to trial characteristics (e.g. treatment arms, population enrolled, patients' characteristics) and patient outcomes [e.g. overall response rate (ORR), OS, progression-free survival, toxicity] were collected. Treatment efficacy outcomes and toxicity were compared according to age.
Although there is lack of a definition of the exact cut-off point at which an adult is considered 'older', we used a cut-off point of ‡70 years since 70 years is a point commonly used in clinical trials in oncology [15] .
statistical analysis
Patients were allocated to the treatment arm indicated by the randomization procedure and analysis was conducted on intention-to-treat basis.
Survival analysis was conducted for time-to-event data, carrying out Cox proportional hazards regression models or Kaplan-Meier curves to assess the prognostic values of the variables of importance.
Chi-square tests and binary logistic regression were conducted to evaluate relationships involving response to treatment and age.
Meta-analysis methods for individual patient data were used for the assessment of the end points of interest. Primary end points for the meta-analysis were OS and time to tumor progression (TTP). Secondary end points were response rate and toxic effects. OS was defined as the time elapsed from randomization till death or last follow-up. Patients who were lost or alive at the time of the last follow-up were considered censored for OS. TTP was defined as the time from randomization till progression of the disease or death. Lost or no progressed patients at the time of the last follow-up were considered censored for TTP.
Heterogeneity of the data among the studies was estimated using Cochran's chi-square test and I 2 index, which quantifies the degree of the heterogeneity between studies. Fixed effects model or random effects models were used to the best evaluation of the overall effects of the studies, taking into consideration the variation of the studies while also carrying out sensitivity analysis when needed.
results patients
Five randomized phase III studies were identified (Table 1) , enrolling a total of 1845 patients; four of these studies have already been published [16] [17] [18] [19] and for one the manuscript is submitted for publication. In the trials included in this meta-analysis, patient characteristics were well balanced between control and experimental arms ( Table 2 ). The number of older patients participating in each study is presented in Figure 1 . These studies enrolled a total of 424 (23% of the total population) older ( ‡70 years of age) and 1421 (77% of the total population) younger (<70 years) patients. There was no statistically significant difference between young and older patients concerning the patient [sex, performance status (PS), smoking status] or the disease (stage, histology, grade) characteristics (data not shown). Furthermore, no significant difference was observed in all trials concerning the percentage of patients who received second-line chemotherapy. The percentage of young patients who received second-line treatment was 45.3%, whereas the corresponding percentage for the older population was 41.4% (P = 0.743).
overall response rate
Data about objective response were available for all five studies and all patients and were analyzed based on an intention-totreat analysis. The odds ratio for nonresponse (among patients <70 years of age versus those ‡70 years of age) was 1.15 [95% confidence interval (CI) 0.90-1.46; P value = 0.27] (Figure 2 ), a nonsignificant difference. The result of the test for heterogeneity among the studies was not statistically significant (v 2 test = 1.83; P value = 0.77), and the I 2 index (0%) indicated that variability across trials was due to chance rather than heterogeneity (Table 3) .
time to tumor progression
Data about TTP were available from all five studies. Median TTP was similar between young and older patients in all five studies (3.8 versus 4.0 months). The analysis demonstrated that the risk for progression was not higher in older patients [hazard ratio (HR): 1.00, 95% CI 0.89-1.12; P value = 0.97] (Table 4) . Moreover, there was a trend toward heterogeneity between treatment effects on TTP among trials (v 2 test = 8.27; P value = 0.08; I 2 index 52%). When the analysis was carried out after omitting the CT/96.16 trial [16] , which showed a different trend, the results showed a more homogenized patient cohort indicating that most of heterogeneity in the meta-analysis was related to this single study (v 2 test = 1.11; P value = 0.77; I 2 index 0%). toxicity Older patients were more likely to experience severe (grade III/ IV) hematologic and non-hematologic toxicity compared with their younger counterparts (Table 6 ). Differences were more pronounced in the case of non-hematologic toxicity. For hematologic toxic effects, the HR was 1.19 (95% CI 0.90-1.57; P value = 0.22). As it concerns non-hematologic toxicity, HR was 1.93 (95% CI 1.39-2.68; P value <0.0001). In total, there were 149 (35.1%) events of grade III/IV toxicity in older patients compared with 370 (26.04%) events in younger patients (HR: 1.44, 95% CI 1.16-1.78; P value = 0.0008).
discussion
The first observation of this retrospective review of HORG's phase III trials is that older patients are clearly underrepresented in clinical trials evaluating new regimens as first-line treatment of advanced/metastatic NSCLC. This observation is in accordance with similar observations reported by other groups [10, 20, 21] in several tumor types. An analysis reported by the Southwest Oncology Group yielded that the proportion of older cancer patients ( ‡65 years of age) enrolled in their clinical trials was significantly less compared with the percentage of older patients in the USA population of patients with cancer (25% versus 63%, respectively; P value <0.001).
When the age cut-off was set at 70 years, these proportions were 13% and 47%, respectively (P value < 0.001) [22] . Furthermore, a significant underrepresentation of the older cancer patients was reported in registration trials for new anticancer agents, with the exception of hormonal treatment for breast cancer, and this underrepresentation was even greater for patients ‡70 years [10] .
Several barriers to the recruitment of older patients to cancer clinical trials have been reported [23] . However, the main reason for underrepresentation of elderly patients in experimental clinical trials has been the reluctance of treating physicians to enroll older patients on to clinical trials because of limited expectations for long-term benefits and because of the misbelief that older patients cannot, in general, tolerate the treatmentrelated toxic effects [24, 25] . It should be underlined that the percentage of older NSCLC patients participating in HORG's clinical trials has raised from 17% in the older trial included in this analysis [16] to 28% in the most recent trial (A. G. Pallis, A. Athanasiadis, S. Aggelaki et al., in press, Forum of Clinical Oncology). This observation suggests that treating physicians are more willing to enroll older patients in clinical trials probably due to the increasing bank of data demonstrating that older NSCLC patients can be safely treated [26] .
The second observation of the current trial is that older patients received the same benefit from treatment as their young counterparts, in terms of ORR, TTP, and OS. Although survival analysis showed a significant difference in favor of younger patients, it should be noted that one trial (HORG 96.16 trial) showed a different trend with a statistically significant OS difference in favor of young patients. It is not quite clear why this difference was observed. However, it should be noted that this trial was the first randomized phase III trial carried out by our group in the field of metastatic NSCLC, with the smallest percentage of older patients enrolled. Furthermore, this trial showed a trend toward higher percentage of patients with a PS of two in the older patient group compared with the younger group (percentage of patients with PS 2; <70 years versus ‡70 years: 67.8% versus 78.9%; P value = 0.066). When analysis was carried out after omitting this trial, no significant difference was observed between younger and older patients. Our findings are in line with the previous reports on this topic presented by several groups [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] that demonstrated similar efficacy outcomes between older and younger patients.
On the basis of these observations, it could be supported that older patients should be treated in the same way as their younger corresponding patients. However, this conclusion is questionable. First of all, the vast majority of these data is derived from retrospective analyses, which are highly likely to suffer from selection bias since only the 'fittest' older patients would have been enrolled in these trials [40] . Thus, the results of these analyses cannot be automatically extrapolated to the general older population because the enrolled patients are not representative of the general senior population. Furthermore, many studies, including the current one, report significantly more toxicity for older patients [27, 30, 33-37, 39, 41] compared with young patients receiving the same treatment. Moreover, it has been reported that older NSCLC patients participating in age-specific trials presented lower rates of severe adverse events compared with older patients participating in clinical trials without upper age limit (grade ‡III non-hematologic toxicity, 57% versus 81%, respectively; P value <0.001; grade ‡III hematologic toxicity, 10% versus 68%, respectively; P value <0.001) without significant differences in survival [42] . These observations imply that not only the inclusion of older patients in no-age-limit trials is questionable as for generalization of results but it also might be hazardous for older population because such trials are associated with higher rates of severe toxicity. That fact clearly demonstrates the need for a more tailored approach to this special population. These age-specific prospective trials will allow the development of evidence-based clinical recommendations that apply to the treatment of the older patients [8] . In case that age-specific trials are not possible then, a sufficient number of older patients should be enrolled in trials Test for overall effect Z = 1.09, P = 0.27 CI, confidence interval; IV, inverse variable. Test for overall effect Z = 0.04, P = 0.97 SE, standard error; CI, confidence interval; IV, inverse variable. original article Annals of Oncology designed for general population. These patients should be representative of the general older population, thus allowing the generalization of the results [43] . Another limitation to the generalization of the observations of the current meta-analysis is the fact that some of the trails included in the meta-analysis base their control arm to platinum-free regimens that are not 'standard' according to the current practice. However, it should be noted that these trials are old and at the time they were planed, platinum-free doublets were considered an acceptable alternative [44] .
Additionally, the generalization of the findings reported in the current study is limited by the heterogeneity observed among older patients of the same chronological age. Some patients are likely to benefit from standard cancer treatment as their younger counterparts do, while others who present with several comorbidities and significant functional impairment are at higher risk of experiencing severe treatment-related toxicity, requiring treatment modifications [44] . Therefore, there is a need for an effective tool that will allow the selection of patients suitable for either standard or attenuated therapy. Unfortunately, there is a lack of validated and widely accepted aging biomarkers, although several have been proposed [45] [46] [47] . A useful tool for the selection of patients suitable for treatment is comprehensive geriatric assessment (CGA), which categorizes the patients according to their global and functional status into (i) fit (without serious comorbidities and no dependence), (ii) frail (with significant comorbidities and dependency), and (iii) vulnerable (with some dependency-as assessed by the Instrumental Activities of Daily Life questionnaire [48] -with or without severe comorbidities). Patients in the first group have similar prognosis and treatment tolerance and outcome compared with their younger counterparts [30, 49, 50] . Patients in the second group are usually offered only best supportive care, while patients in the third group, which is the largest, demand more tailored and personalized approaches. Furthermore, CGA will allow the identification of potentially treatable problems (such as depression or malnutrition) that may otherwise decrease tolerability and increase toxicity and consequently to compromise the outcome.
This report adds to the bank of data that support the feasibility of chemotherapy treatment of older NSCLC patients. Moreover, the optimization of treatment of older NSCLC patients requires the development of validated markers for evaluating the 'functional' rather than the chronological age and the design of prospective older-specific phase III trials for each functional group of these patients.
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